Key Highlights

  • OrthoPediatrics (NASDAQ:KIDS) rose 30.6% intraday on October 28, 2026, as of about 3 p.m. ET, after reporting record third-quarter revenue of USD 72.7 million, up 19%.
  • The company raised its full-year revenue forecast to a range of USD 270 million to USD 273 million, per the company release, a signal that management expects growth to continue.
  • The 30.6% gain is an intraday figure from published market data at 3 p.m. ET, so the final close could differ from the number quoted for OrthoPediatrics (NASDAQ:KIDS).
  • Simple arithmetic on the reported growth rate puts third-quarter revenue a year earlier near USD 61.1 million, about USD 11.6 million lower than the new record.

What OrthoPediatrics Reported

OrthoPediatrics (NASDAQ:KIDS) reported record third-quarter revenue of USD 72.7 million on October 28, 2026, up 19% from a year earlier, according to the company release. It also raised its full-year revenue forecast to USD 270 million to USD 273 million. The shares were up 30.6% at about 3 p.m. ET, according to published market data, so the closing move may differ. The company focuses on orthopedic implants and instruments designed for children, a specialized segment with fewer competitors than adult orthopedics. The data reviewed did not include profit figures, cash or the prior forecast range. Pediatric orthopedics has to account for growing bones, which makes products more specialized. Pediatric products need sizes that fit growing patients.

Why Records and Raised Guidance Matter

Record revenue shows demand is still rising, and a raised forecast shows management expects more. For a company serving a niche market, growth of 19% suggests it is gaining share or expanding hospital adoption. Our arithmetic on two published numbers, dividing USD 72.7 million by 1.19, puts the prior-year quarter near USD 61.1 million, an increase of about USD 11.6 million. The forecast range of USD 270 million to USD 273 million is narrow, which signals management confidence in visibility. Guidance that rises alongside strong results often prompts analysts to lift estimates, which can add to buying pressure in a smaller stock. Record results also give management a stronger base for next year's planning.

Risks and What to Watch

A 30.6% jump in one session increases the pressure to deliver. OrthoPediatrics (NASDAQ:KIDS) must keep hospitals buying, manage inventory of implant sets and absorb costs, and any shortfall against the forecast could prompt a sharp reversal. The intraday figure may also change by the close. Watch for the final closing price, analyst estimate changes, the fourth-quarter report and any commentary on margins. Smaller medical-device names can also move with broader sentiment, and Nasdaq-100 futures were down 1.2% at 4:09 a.m. ET on October 29, suggesting a cautious start for growth stocks. A cautious or delayed hospital purchasing cycle would also show up quickly in quarterly revenue.

Where Things Stand

Record sales and a higher forecast explain it. OrthoPediatrics (NASDAQ:KIDS) rose 30.6% intraday on October 28, 2026 after record third-quarter revenue of USD 72.7 million, up 19%, and a raised full-year forecast of USD 270 million to USD 273 million. The market is rewarding growth and confidence, though the figure is an intraday reading and profit data were not reviewed. The next test is whether the fourth quarter delivers on the higher outlook. Final close figures should be checked.